EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 3.0

The Efficacy and Safety of Telitacicept versus the Recommended Regimens in IgA Nephropathy: A Single-Center Experience

Xueting Li, Yinghui Zhang, Chenyun Xu, Ben Ke iD

Drug Design, Development and Therapy · 2026-07 · Volume 20 · 1-11

DOI: 10.2147/dddt.s618596 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Drug Design, Development and Therapy, 2026-07. Verfasst von Xueting Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Glucocorticoids. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGAGlucocorticoidsHumansFemaleMaleAdultMiddle AgedTreatment OutcomeYoung AdultRecombinant Fusion Proteins

Stichwörter der Autor:innen

IgA nephropathyglucocorticoidsnefeconproteinuria reduction ratetelitacicept

Substanzen

GlucocorticoidstelitaciceptRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China.

ORCID-Profile: Ben Ke

Zitieren

APA

Li, X., Zhang, Y., Xu, C., & Ke, B. (2026). The Efficacy and Safety of Telitacicept versus the Recommended Regimens in IgA Nephropathy: A Single-Center Experience. Drug Design, Development and Therapy, Volume 20, 1-11. https://doi.org/10.2147/dddt.s618596

Vancouver

Li X, Zhang Y, Xu C, Ke B. The Efficacy and Safety of Telitacicept versus the Recommended Regimens in IgA Nephropathy: A Single-Center Experience. Drug Design, Development and Therapy. 2026;Volume 20:1-11. doi:10.2147/dddt.s618596

BibTeX
@article{Li2026,
  author = {Li, Xueting and Zhang, Yinghui and Xu, Chenyun and Ke, Ben},
  title = {The Efficacy and Safety of Telitacicept versus the Recommended Regimens in IgA Nephropathy: A Single-Center Experience},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--11},
  doi = {10.2147/dddt.s618596}
}
Kostenlos starten →